Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
33%(1 trials)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_3
3
60%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 33 (60.0%)
N/A1 (20.0%)

Trials by Status

completed360%
not_yet_recruiting120%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_3

PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).

NCT07025681
not_yet_recruitingphase_1

Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Produced by Nanogen Pharmaceutical Joint Stock Company

NCT06919861
completedphase_3

Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease

NCT04036253
completednot_applicable

Allogeneic UCB Therapy With EPO in Children With CP

NCT01991145
completedphase_3

Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial

NCT01962571

Clinical Trials (5)

Showing 5 of 5 trials
NCT07025681Phase 3

PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).

Recruiting
NCT06919861Phase 1

Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Produced by Nanogen Pharmaceutical Joint Stock Company

Not Yet Recruiting
NCT04036253Phase 3

Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease

Completed
NCT01991145Not Applicable

Allogeneic UCB Therapy With EPO in Children With CP

Completed
NCT01962571Phase 3

Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5